Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21)

Grazia Artioli, Gaia Giannone, Giorgio Valabrega, Furio Maggiorotto, Sofia Genta, Sandro Pignata, Domenica Lorusso, Gennaro Cormio, Simona Scalone, Maria Ornella Nicoletto, Filippo Greco, Emanuela Rossi, Ilaria Spagnoletti, Ugo De Giorgi, Michele Orditura, Anna Maria Mosconi, Anila Kardhashi, Stefano Bogliolo, Lucia Borgato

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE: Around 15% of epithelial ovarian cancer (EOC) patients (pts) harbor a germline BRCA1 or 2 mutation, showing different features than BRCA wild-type pts. The clinical and pathological features of an Italian BRCA mutated EOC cohort were described.

METHODS: We retrospectively analyzed clinical, pathological and mutational data from a cohort of Italian BRCA mutated EOC pts. treated in 15 MITO centers between 1995 and 2017.

RESULTS: Three-hundred thirty-one pts. were recorded. Two-hundred forty (72%) and 91 (27.5%) pts. harbored a BRCA1 and BRCA2 mutation, respectively. Median age at diagnosis was 52 years. The most frequent diagnosis was a high grade serous FIGO III or IV EOC and platinum doublet in first-line was administered to almost all pts. Fifty-three % of them had no residual disease (R = 0) at surgery. Median progression-free-survival (mPFS) after first-line chemotherapy was 29 months. Expected percentage of pts. alive at 5 years was 72.5% (CI 60.2-80.8%) and R = 0 predicted a significantly longer overall survival (OS). Sixty-six pts. (19,9%) had both an EOC and a breast cancer (BC) diagnosis. The first diagnosis was BC in 81,8% of cases with a mean interval between the two diagnoses (IBTDs) of 132.4 months. Mutational data show that the founder mutation c.5266dupC in BRCA1 was the most frequently recorded.

CONCLUSIONS: This is the largest Italian BRCA mutEOC cohort. The only predictor of longer OS was R = 0. EOC pts. that developed subsequently a BC are long-term survivors.

Original languageEnglish
Pages (from-to)755-761
Number of pages7
JournalGynecologic Oncology
Volume161
Issue number3
DOIs
Publication statusPublished - Jun 2021

Fingerprint

Dive into the research topics of 'Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21)'. Together they form a unique fingerprint.

Cite this